ABSTRACT
<p><b>OBJECTIVE</b>To investigate the methylation status of LRP15 gene in acute leukemia (AL) patients and its role in the tumorigenesis.</p><p><b>METHODS</b>The methylation of LRP15 promoter and first exon of bone marrow mononuclear cells in 73 patients with AL, 10 with chronic leukemia (CL), 9 with hematological benign diseases, and 20 healthy transplantation donors was analyzed by using methylation specific polymerase chain reaction. The methylation of LRP15 gene promoter and first exon in COS7, K562, and HL60 cell lines was also assayed.</p><p><b>RESULTS</b>No LRP15 gene promoter methylation was detected in COS7 cell line. LRP15 gene promoter was methylated in K562 and HL60 cell lines. No deletion of LRP15 gene was detected in all samples. In nearly all French-American-British leukemia subtypes, we found that frequency of LRP15 methylation in adult patients with AL was 71.23% (52/73). There was no detectable methylation in any of the 20 healthy donors and 8 chronic myeloid leukemia patients. The difference in frequency of LRP15 methylation between AL patients and healthy donors or CL patients (10.00%, 1/10) was significant (P < 0.01). Hypermethylation of LRP15 gene was found in 57.14% (16/28) of newly diagnosed AL patients, 83.33% of relapsed AL patients respectively, which was significantly different (P < 0.05). We also demonstrated LRP15 methylation in 55.56% (5/9) adults with benign hematological diseases.</p><p><b>CONCLUSIONS</b>LRP15 methylation changes are common abnormalities in leukemia. LRP15 is postulated to be a tumor suppressor gene.</p>
Subject(s)
Animals , Humans , Acute Disease , Base Sequence , COS Cells , Cell Line, Tumor , Chlorocebus aethiops , DNA Methylation , DNA Primers , Leukemia , Genetics , Neoplasm Proteins , Genetics , Promoter Regions, GeneticABSTRACT
The study was aimed to analyze the characteristics of LRP16 gene promoter and its activity in order to explore the possible regulation mechanism of LRP16 gene expression. A 2.6 kb genomic DNA sequence of LRP16 5'-end was obtained from NCBI by BLAST software. The 7 target sequences between 0.2 - 2.6 kb from a healthy blood donor DNA sample were amplified by PCR, then identified by DNA sequencing and semi-nest PCR. The verified sequences were analyzed on-line. The results showed that the 7 target sequences were about 400 bp different from each other. All 7 sequences were the same to these GenBank described. At last, all 7 promoter sequences were ligated with luciferase vector, and then the luciferase activity was analyzed in HeLa cells. A known gene promoter sequence can be freely obtained from NCBI database. It is concluded that LRP16 promoter is a standard type II promoter and its activity is strongest in the region from -200 to -600 bp.
Subject(s)
Humans , Base Sequence , Chromosomes, Human, Pair 11 , Gene Expression , Luciferases , Metabolism , Molecular Sequence Data , Neoplasm Proteins , Genetics , Promoter Regions, Genetic , Genetics , Sequence Analysis, DNAABSTRACT
To study the methylation in the promoter of LRP15 gene and its relationship with gene expression and to explore the possible mechanism of regulating LRP15 gene methylation, the methylation in the promoter of LRP15 gene in K562 cell line was detected by MS-PCR. Then K562 was exposed to 5-aza-2'-deoxycytidine (CdR) and trichostatin (TSA), to determine whether the silencing of LRP15 gene by de novo methylation could be reversed. As a result, it was confirmed by MS-PCR that the promoter of LRP15 was hypermathylated in K562 cell line, and lost its transcription activity. After CdR, with or without TSA, the silencing of LRP15 gene by de novo methylation can be reversed. Observation demonstrated that the expression of LRP15 was controlled by methylation in its promoter in K562. It is suggested that methyltransferase inhibitor and deacetylase inhibitor may be effective agents in leukemia therapy.
Subject(s)
Humans , Azacitidine , Pharmacology , DNA Methylation , DNA Modification Methylases , Enzyme Inhibitors , Pharmacology , Gene Expression Regulation , Histone Deacetylase Inhibitors , Hydroxamic Acids , Pharmacology , K562 Cells , Neoplasm Proteins , Genetics , Polymerase Chain Reaction , Methods , Promoter Regions, Genetic , GeneticsABSTRACT
In order to observe the effect of inhibitors for demethylation and histone deacetylase on the growth of leukemia cell line K562 and the expressin of tumor related genes, the K562 cells were treated with 5-aza-2' deoxycytidine (DAC) and trichostatin A (TSA) in co-culture; the growth curves were observed; the cell cycle was detected by flow cytometry (FCM); the gene expression pattern before and after drug treatment was measured with Atlas7742-1 microarray. The results showed that the combination treatment of DAC and TSA inhibited the proliferation of K562 cells, the growth of most cells were stopped in G(1)/S phases after drug treatment, the gene expression after treatment was more than before, and a few gene expression were down-regulated. In conclusion, combination treatment of DAC and TSA had an inhibitive effect on the leukemia cell line K562, combination of DAC and TSA with microarray could be used for screening candidate genes inhibiting leukemia cells.
Subject(s)
Humans , Azacitidine , Pharmacology , Cell Cycle , Cell Division , DNA Methylation , Enzyme Inhibitors , Pharmacology , Histone Deacetylase Inhibitors , Hydroxamic Acids , Pharmacology , K562 CellsABSTRACT
To explore the possible function of LRP15 gene in carcinogenesis and its significance in the classification and prognosis of leukemia, the expression pattern of LRP15 in normal tissues, tumor tissues and cell lines was detected with SAGE and gene expression database provided by NCBI and NCI respectively. RT-PCR was used to detect the expression of LRP15 in leukemia patients. The results showed that LRP15 was expressed in different tissues and tumor cell lines, the positive rate of LRP15 in immature blood cells was higher than that of mature blood cells and the positive rate of M(1), M(2) and M(3) was higher than that of other AML subtypes (P < 0.01), the expression of LRP15 in refractory leukemia was higher than that of de novo leukemia. The results suggest that LRP15 may play an important role in carcinogenesis, AML classification and acute leukemia prognosis.
Subject(s)
Humans , Cell Line, Tumor , Gene Expression Profiling , Leukemia , Genetics , Neoplasm Proteins , Proteins , GeneticsABSTRACT
To clone the full length cDNA of a novel leukemia relapse-associated candidate gene (LRP15), the human ESTs (Expression Sequence Tags) fragments obtained from electronic hybridization were assembled by a 1.8 kb DNA probe, which was only methylated in relapsed leukemia. Then the primers were designed for rapid amplification of cDNA end (RACE). Bioinformatic data of High Throughout Genomic Sequences (HTGS) and Serial Analysis of Gene Expression (SAGE) were used for chromosome localization and tissue expression analysis. The results showed that the full-length cDNA of the novel gene had an open reading frame of 780 bp encoding a 259 amino acid protein of unkown functions. LRP15 gene expressed in many different tissues was localized in chromosome 3p24. It is concluded that RACE is an effective method to clone novel genes and LRP15 may be a leukemia relapse-associated candidate gene playing an important role in carcinogenesis.